The cut-off values indicating low-risk (0.3) and high-risk (2.0) for the development of a clinically manifest AKI were chosen according to the current recommendations of the manufacturer Nephrocheck (bioMerieux, France) providing the AKI risk assessment tool based on the biomarkers [TIMP-2]⋅[IGFBP-7]. This evidence concerns the gene TIMP2 and acute kidney injury.